Pillar Biosciences Inc., a Natick, MA-based startup specialized in next generation sequencing (“NGS”)-based clinical oncology testing, received US$18m in venture capital.
ORI Capital’s ORI Healthcare Fund made the investment.
The company intends to use the funds to continue its R&D efforts in tumor tissue genotyping area, i.e. integration of back-end information analytics capability, as well as adding liquid biopsy products for cancer therapeutic decision-making and treatment monitoring.
Pillar Biosciences leverages patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit to provide a targeted sequencing method for NGS-based oncology testing.
The startup has released the beta version of Lung & Colon Cancer Somatic Mutation Panel and BRCA1 & BRCA2 Germline Mutation Panel to cancer centers and clinical testing companies in US and China for validation studies.